Re: Intravenous infusion of auto serum-expanded autologous mesenchymal stem cells in spinal cord injury patients: 13 case series

(2021) on the dramatic functional improvement of spinal cord injury by intravenous administration of autologous mesenchymal stem cells [1]. If we focus on the improvement of motor function, which the author shows us as figures, in 7 cases (7/13 = 53.8%), cases 2, 3, 4, 5, 6, 7, and 8, the functional...

Full description

Saved in:
Bibliographic Details
Published in:Clinical neurology and neurosurgery 2021-06, Vol.205, p.106641-106641, Article 106641
Main Authors: Shigematsu, Kazuo, Yamagishi, Hisakazu
Format: Article
Language:English
Subjects:
Alzheimer's disease
Autografts
Demyelinating diseases
Demyelination
Immunomodulation
Intravenous administration
Mesenchymal stem cells
Multiple sclerosis
Myelination
Neurodegenerative diseases
Neurology
Regeneration
Spinal cord injuries
Spontaneous recovery
Stem cells
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:(2021) on the dramatic functional improvement of spinal cord injury by intravenous administration of autologous mesenchymal stem cells [1]. If we focus on the improvement of motor function, which the author shows us as figures, in 7 cases (7/13 = 53.8%), cases 2, 3, 4, 5, 6, 7, and 8, the functional improvement was noticeable even before MSC administration, so perhaps the subsequent improvement includes spontaneous recovery. If, as the authors state, the effects of MSC administration include remyelination, immunomodulation, and promotion of axonal regeneration of damaged neurons, then MSC administration may be effective not only for spinal cord injury but also for demyelinating diseases such as multiple sclerosis and neurodegenerative diseases such as ALS and Alzheimer's disease [3].
ISSN:0303-8467
1872-6968
DOI:10.1016/j.clineuro.2021.106641